ASCO 2025 | ECOG-ACRIN EA6194: neoadjuvant pembrolizumab & vidutolimod in melanoma
Ahmad Tarhini, MD, PhD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses the Phase II ECOG-ACRIN EA6194 trial (NCT04708418), which evaluated neoadjuvant pembrolizumab alone or with intratumoral vidutolimod in patients with resectable stage IIIB–D cutaneous melanoma. The combination demonstrated an acceptable safety profile and a higher rate of major pathologic responses compared with pembrolizumab alone. These findings suggest that adding vidutolimod may enhance neoadjuvant efficacy without substantially increasing toxicity, supporting continued investigation in this patient population. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
